Retraction to: Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia (Leukemia & Lymphoma, (2013), 54, 7, (1521-1526), 10.3109/10428194.2012.754888);Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1521-1526

  Liu, Fang ^a   Gao, Li ^a,b   Jing, Yu ^a   Xu, Yuan Yuan ^a   Ding, Yi ^a   Zhou, Min Hang ^a   Ma, Chao ^a   Li, Mian Yang ^a   Sun, Jun Zhong ^a   Wang, Li Li ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Acute lymphoblastic leukemia; Gene rearrangements; Multiplex nested RT PCR

Indexed keywords

BCR ABL PROTEIN; HOX PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHINESE; CHROMOSOME ANALYSIS; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84879333098     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2020.1794540     Document Type: Erratum

References (35)

1. Cornell RF, Palmer J. Adult acute leukemia. Dis Mon 2012;58 : 219-238.
2. Ma J, Wu M. The indicative eff ect of Notch1 expression for the prognosis of T-cell acute lymphocytic leukemia: a systematic review. Mol Biol Rep 2012; 39: 6095-6100.
3. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012;39:47-57.
4. Harrison C J. Acute lymphoblastic leukemia. C lin Lab Med 2011;31:631-647.
5. Campos-Sanchez E, Toboso-Navasa A, Romero-Camarero I, et al. Acute lymphoblastic leukemia and developmental biology: a crucial interrelationship. Cell Cycle 2011;10:3473-3486.
6. Yeung DT, Parker WT, Branford S. Molecular methods in diagnosis and monitoring of haematological malignancies. Pathology 2011;43:566-579.
7. Sarmento LM, Barata JT. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev Anticancer Ther 2011;11:1403-1415.
8. Wu CP, Qing X, Wu CY, et al. Immunophenotype and increased presence of CD4(-)CD25(-) regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett 2012; 3: 421-424.
9. Morrissette JJ, Bagg A. Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. Clin Lab Med 2011;31:659-686, x.
10. Harrison CJ, Haas O, Harbott J, et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankf ü rt-M ü nster study group. Br J Haematol 2010; 151: 132-142.
11. Pallisgaard N, Hokland P, Riishoj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574-588. (Pubitemid 28323721)
12. Ariffin H, C hen S P, W ong H-L, et al. V alidation of a multiplex RT-PCR assay for screening significant oncogne fusion transcripts in children with acute lymphoblastic leukemia. Singapore Med J 2003;44:517-520. (Pubitemid 38649139)
13. Elia L, Mancini M, Moleti L, et al. Amultiplex reverse transcriptionpolymerase chain reaction strategy for the diagnosis molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica 2003;88:275-279. (Pubitemid 36361982)
14. Sun J, Wang Z, Luo Y, et al. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph-acute myeloid leukemia. Acta Haematol 2012;127:143-148.
15. H ornakova T, S pringuel L, D evreux J, et al. O ncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011; 96: 845-853.
16. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in highrisk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414-9418.
17. De Braekeleer M, Morel F, Le Bris MJ, et al. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res 2005; 25: 1931-1944. (Pubitemid 40904588)
18. Ravindranath Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 2003;15:23-35. (Pubitemid 36135644)
19. B é n é MC, Porwit A. Acute leukemias of ambiguous lineage. Semin Diagn Pathol 2012; 29: 12-18.
20. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999;36:59-72.
21. Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. Oncogene 2001;20:5708-5717. (Pubitemid 32928108)
22. Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003:102-131.
23. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004;23:4275-4283. (Pubitemid 38765136)
24. Sawińska M, Ła don D. Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suff ering from acute lymphoblastic leukaemia. Leuk Res 2004;28:35-42. (Pubitemid 37433791)
25. K ebriaei P, A nastasi J, L arson R A. A cute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 2002; 15: 597-621.
26. Pan J, Zou J, Wu DY, et al. FUS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal diff erentiation of myeloid progenitor cells. Mol Cancer Res 2008;6 : 862-872.
27. Kanazawa T, Ogawa C, Taketani T, et al. TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease. Leuk Lymphoma 2005;46:1833-1835. (Pubitemid 43203122)
28. Mansur MB, Emerenciano M, Brewer L, et al. SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leuk Lymphoma 2009; 50: 1318-1325.
29. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci 2011;102 : 1874-1881.
30. Von Lindern M, Breems D, van Baal S, et al. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undiff erentiated leukemia. Genes Chromosomes Cancer 1992;5:227-234.
31. Özbek U, Kandilci A, van Baal S, et al. SET-CAN, the product of the t(9;9) in acute undiff erentiated leukemia, causes expansion of early hematopoetic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol 2007;171:654-666. (Pubitemid 47344697)
32. Saito S, Nouno K, Shimizu R, et al. Impairment of erythroid and megakaryocytic diff erentiation by a leukemia associated and t(9;9)-derived fusion gene product, SET/TAFI-CAN/Nup214. J Cell Phys 2007;214:322-333.
33. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008; 111: 4668-4680.
34. Ravinet A, Gay Belille M, Lemal R, et al. Physiopathological, diagnostic and therapeutic impacts of chromosomal translocations in hematological malignancies. Bull Cancer 2011; 98: 1403-1418.
35. Graux C. Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance. Transfus Apher Sci 2011; 44: 183-189.